Nezuro, US FDA yakazivisa kubvumidzwa kweSeattle Genetics 'antibody-drug conjugate Adcetris (brentuximab vedotin) pamwe chete nechemotherapy kune varwere vakamborapwa nhanho III kana IV classic Hodgkin's lymphoma (cHL). Iyi mvumo inomiririra kuvandudzwa kwechirongwa chekutanga chekurapa cheiyo yepamusoro Hodgkin lymphoma iyo yakaunzwa mukiriniki tsika makore anopfuura makumi mana apfuura.
Lymphoma is a type of cancer that begins in the lymphatic system. The immune system helps the body fight infections and diseases. Lymphoma can develop almost anywhere in the body and can spread to nearby lymph nodes. It is divided into two types: Hodgkin's lymphoma and non-Hodgkin lymphoma. Most patients with Hodgkin lymphoma belong to the classic type. In this type of lymph node, there are large abnormal lymphocytes (a type of white blood cell). Called Reed-Sternberg cells. Through early intervention, patients with Hodgkin’s lymphoma usually get long-term remission.
Mune kiriniki yekuyedzwa, kugona kweAdcetris kurapa yekare Hodgkin's lymphoma kwakasimbiswa - vaongorori vakabata 1,334 vakarapwa varwere avo vakambogamuchira avhareji yezvikamu zvitanhatu zvemazuva makumi maviri nemasere zvisati zvaitika. Shure kwaizvozvo, vakakamurwa kuita mapoka maviri, rimwe boka rakagamuchira Adcetris uye chemotherapy (AVD), uye rimwe boka rakagamuchira chete chemotherapy (ABVD). Zvidzidzo zvakaratidza kuti varwere vanogamuchira musanganiswa kurapa vane 6% yakaderera njodzi yekuwedzera kwechirwere, kufa, kana kuda kwekutanga kurapwa kutsva zvichienzaniswa nevarwere vanongogamuchira chemotherapy.
Adcetris combines antibodies and drugs, allowing antibodies to direct drugs to lymphoma masero called CD30, approved for treatment of relapsed classic Hodgkin lymphoma, classic Hodgkin lymphoma with high risk of relapse or progression after stem cell transplantation, accepted Systemic anaplastic large cell lymphoma that other treatments are not effective, and primary cutaneous anaplastic large cell lymphoma that does not work with other treatments.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm601935.htm
